Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine maintenance without bone marrow toxicity for elderly acute myeloid leukemia
ChiCTR1800019827Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: 2-year overall survival. Started Dec 2018; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800019827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019827.